Technology developed by 6+ years of research in National University of Singapore.
Platform technology that can adapt to a range of diseases, i.e. Covid-19, Lung cancer, Tuberculosis, etc.
Initial clinical trial has shown over 90% accuracy for Covid-19 detection, and 80% for Lung Cancer detection.
Breathonix looking to raise USD 5 million to expedite our deployment of Covid-19 solution and kickstart clinical trials for other fatal diseases
We are looking to disrupt a USD 55 billion medical diagnostics industry.
Covid-19: Airlines and Checkpoints;
Other fatal diseases: Hospitals and screening centers.
Covid-19 Rapid Mass Screening; Annual Health Screening; Disease diagnostics and management.